Status:
COMPLETED
Comparison of Human Insulin Produced by the Current Process and the NN729 Process in Healthy Volunteers
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Healthy
Eligibility:
MALE
18-50 years
Phase:
PHASE1
Brief Summary
This trial is conducted in Europe. The aim of this trial is to show that the product of the new production process has a similar pharmacological profile to the traditional process used for the current...
Eligibility Criteria
Inclusion
- Normal findings in medical history and physical examination unless the investigator considers any abnormality to be clinically irrelevant
- Fasting blood glucose below or equal to 6 mmol/L
- Body Mass Index (BMI) 22.0-27.0 kg/m\^2 (both inclusive)
Exclusion
- Participated in another clinical study with an investigational drug within the last 4 weeks
- Any condition requiring the regular use of any medication, including herbal remedies, over the counter medicines and vitamins. Occasional paracetamol is acceptable
- Known or suspected allergy to the trial product or related products
- Family history of type 1 diabetes
Key Trial Info
Start Date :
October 15 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 20 2002
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT01448070
Start Date
October 15 2002
End Date
December 20 2002
Last Update
February 27 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Manchester, United Kingdom, M15 6SH